AstraZeneca Archives

News and Trends 16 Sep 2022

CHMP recommends approval of Beyfortus for prevention of RSV disease in infants

Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of RSV lower respiratory […]

September 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Ionis presents positive study results at International Symposium on amyloidosis

Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 11 Aug 2022

Acquisition of TeneoTwo and its clinical-stage T-cell engager completed

AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug candidate. The company made an upfront payment of $100 million and then additional payments of up to $805 million contingent on research and development milestones as well as up to $360 million to TeneoTwo’s former […]

August 11, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca

A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate (ORR) in patients. AstraZeneca and HUTCHMED announced that TAGRISSO Plus Savolitinib – a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor – was helping patients with high levels of mesenchymal epithelial transition (MET). […]

August 8, 2022 - 3 minutesmins - By Liza Laws

In Depth 14 Jul 2022

Radiopharmaceuticals gain traction for cancer theranostics potential

After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or “theranostics.” Over the last few years, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this […]

July 14, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 5 Jul 2022

AstraZeneca adds to its treatments for blood cancer with $100M deal

AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […]

July 5, 2022 - 2 minutesmins - By Liza Laws

decentralized trial virtual clinical trial

News and Trends 29 Jun 2022

Global call for scientists and inventors to form new startup

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

June 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Jun 2022

Upstream Bio to target asthma as it launches with $200M financing

Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […]

June 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Feb 2022

Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials

Despite the widespread rollout of vaccines over 2021, the Covid-19 pandemic remains a threat to healthcare systems worldwide. Numerous treatments and vaccines are hitting the late-stage pipeline, which could greatly expand the anti-Covid-19 arsenal. Two years ago, the Covid-19 pandemic swept the world and left economic disruption, healthcare crises, and widespread lockdowns in its wake. […]

February 15, 2022 - 7 minutesmins - By Jonathan Smith

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 11 May 2021

ADC Approval Buoys Spirits in Cancer Treatment Space

The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […]

May 11, 2021 - 7 minutesmins - By Jonathan Smith

News and Trends 9 Feb 2021

EMA Green Light Sends Oxford Covid-19 Vaccine Into Turbulent Market

As AstraZeneca and the University of Oxford’s Covid-19 vaccine debuts in the EU market this month, supply bottlenecks, viral variants, and political squabbles demonstrate that the quest to develop and distribute Covid-19 vaccines is far from over. The list of approved Covid-19 vaccines in Europe is growing ever longer with the EMA approval of the […]

February 9, 2021 - 6 minutesmins - By Kostas Vavitsas

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us